CVRx, Inc. (CVRX)

Over the past six months, CVRx's stock has experienced several notable events. CVRx reported Q4 2025 revenue of $16.02 million, exceeding analyst expectations, and full-year 2025 revenue of $56.7 million, a 10% year-over-year growth. The introduction of new Category I CPT codes, effective January 1, 2026, eliminated the need for automatic prior authorization denials, which is expected to accelerate growth. The initiation of the pivotal BENEFIT-HF trial under CMS Category B IDE coverage is a crucial advancement that could potentially triple CVRx's addressable market. Canaccord Genuity maintained a Buy rating on CVRx, with a consensus analyst target implying significant upside. An insider buying report for CVRx was noted on February 23, 2026.

CVRx's products and services exhibit demand seasonality. The first quarter of the year typically experiences a dip in demand, referred to as "seasonal softness," as patients may delay scheduling procedures and treatments. Despite these short-term headwinds, the demand for CVRx's Barostim is considered inelastic due to its life-saving nature and limited competing options for heart failure patients.

CVRx, Inc. is a commercial-stage medical device company focused on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company's primary product is the Barostim™ System, the world's first FDA-approved implantable baroreflex activation therapy designed to improve symptoms in patients with heart failure with reduced ejection fraction (HFrEF). The company is also exploring new therapeutic applications for its neuromodulation platform, including the potential pursuit of a full PMA for resistant hypertension.

CVRx distributes its products through a direct sales force, sales agents, and independent distributors across the United States, Germany, and other international markets. As of December 31, 2025, the company had 252 active implanting centers in the U.S. U.S. sales territories grew to 53 by the end of 2025. In Europe, revenue for 2025 was $4.8 million, an increase of 16% over the prior year, with total revenue units increasing to 219. The majority of CVRx's revenue is derived from the USA market.

In the past year, CVRx's brand reputation has been impacted by legal investigations related to securities fraud. Several law firms announced investigations into potential claims on behalf of purchasers of CVRx common stock. These investigations stem from disclosures made by CVRx in April and May 2025 regarding persistent salesforce issues and an underestimation of necessary salesforce restructuring, which led to sharp declines in the stock price.

CVRx, Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. Major institutional owners include Johnson & Johnson, NEA Management Company, LLC, Vanguard Group Inc, and BlackRock, Inc. The largest individual shareholder is Johnson Johnson, owning 7.52 million shares, representing 28.58% of the company.